TGFB1 and glioblastoma: Another strategy encompasses the application of UCB-derived NK cells expressing the TGF-β-dominant-negative receptor II (DNRII) which can consume TGF-β molecules to reduce the immune-suppressive capacity of TGF-β in the tumor environment of glioblastoma [101].